iwCAR-T 2023 | Updates in CLL
In this exclusive session, John Gribben, MD, DSc, FRCP, FRCPath, FMed Sci Barts Cancer Institute, London, UK, Tanya Siddiqi, MD, City of Hope National Medical Center, Duarte, CA, and Joseph Melenhorst, PhD, Cleveland Clinic, Cleveland, OH, explore the latest updates in CAR-T therapy for chronic lymphocytic leukemia (CLL), delving into the intrinsic T cell defects in CLL, the TRANSCEND study (NCT03331198), the use of ibrutinib with CD19 CAR-T therapy, and continue with the impact of previous chemoimmunotherapy on response to CAR-T, and strategies to overcome resistance to CAR-T in CLL. This discussion took place at the 5th International Workshop on CAR-T (iwCAR-T) 2023 held in Miami, FL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
